Physician profile
Natalie Ricks
NPI 1801178033
$5,826.22
in general payments reported to CMS, 2019-2025
22 companies · $855 in 2025
The $855 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $737 · 2022: $1,442 · 2023: $1,581 · 2024: $1,211 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,563.83 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $858.84 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $836.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $812.16 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $669.72 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $588.52 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $417.04 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $410.56 | 2021-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $262.74 | 2022-2025 | Sotyktu |
| Ucb, INC. | $216.63 | 2022-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $178.61 | 2021-2024 | |
| Amgen INC. | $114.66 | 2021-2024 | Otezla |
| Incyte Corporation | $96.70 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $72.00 | 2024-2025 | Zoryve |
| Almirall LLC | $54.71 | 2023 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.86 | 2024 | Duobrii, Targretin, Siliq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $41.92 | 2025 | Lumenis Pulse 120h |
| Genentech USA, INC. | $32.63 | 2021-2022 | |
| Galderma Laboratories, L.P. | $31.52 | 2023-2025 | Epsolay, Oracea, Aklief |
| Mallinckrodt Hospital Products INC. | $28.12 | 2024 | Acthar |
| Organon LLC | $17.20 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.17 | 2025 | Nuzyra |
| Smith+Nephew, INC. | $16.87 | 2023 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Ricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.